Immunotherapeutic Targeting of the STING Pathway to Combat Neuroblastoma

Background

The stimulator of interferon genes (STING) pathway is known to be critical for generating immune responses to tumors. But the role of STING activation has not yet been investigated in neuroblastoma (NB). Therefore, there is a unique opportunity to investigate the efficacy of STING-activating therapeutics as a novel treatment for NB.

Project Goal

We hypothesize that an effective and highly translatable immunotherapy for NB may be achieved by combining therapeutics that target the STING pathway with the nanoparticle delivery technologies developed in the Wilson Lab. This novel approach has unparalleled potential to uncover the role of the STING pathway in NB. The proposed research will lead to further investigation and characterization of this new immunotherapeutic target for NB. It has the potential to ultimately improve the prognosis of NB.